Aeterna Phase I Results Support Cancer Compound
Posted on: Monday, 27 November 2006, 12:01 CST
Aeterna Zentaris has disclosed additional positive phase I results for its compound AN-152 in patients with gynaecological and breast cancers.
Further data showed the compound's good safety profile and established the maximum tolerated dose, which will be the recommended dose for a phase II trial. In addition to good safety data, the trial provided a hint of efficacy as disease stabilization and regression of lesions were observed.
Human breast, endometrial and ovarian cancers commonly express receptors for luteinizing hormone-releasing hormone (LHRH-R). High-affinity binding sites for LHRH are found in 52% of human breast cancers, as well as in 80% of human ovarian and endometrial cancers. LHRH-R can be used for targeted chemotherapy with AN-152.
"This additional data provides further proof of concept that the chemical linkage of doxorubicin and the luteinizing hormone-releasing hormone part of the drug molecule is stable in human blood. Most importantly, we witnessed a good safety profile and a hint of efficacy enabling us to establish a suitable dose for further development of AN-152 in the treatment of various cancers," said Dr Jurgen Engel, executive vice president of global research and development at Aeterna Zentaris.
"This targeted approach is an additional example of personalized therapy which is becoming more and more the way of the future," said Gilles Gagnon, president and CEO of Aeterna Zentaris.
Source: Datamonitor
Related Articles
- Short-Term Hormone Therapy And Intermediate Dose Radiation Increases Survival For Early Stage Prostate Cancer
- NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
- Good Data Integrates On-Demand Analytics Service With NetSuite's SuiteCloud Platform
- 29th Annual Building Safety Week "Daily Doses" of Consumer Safety Tips and Interactive Media Tools
- Pharmasset Initiates Dosing for Additional Cohorts in Phase I Hepatitis Trial
- New Patient Database Enables Presentation of Safety, Efficacy Data for Cryoablation
- Calando Pharmaceuticals' Lead siRNA Anti-Cancer Therapeutic Candidate Shown to Be Well Tolerated in Non-Human Primate Safety Study
- Cancer Researcher Admits to Faking Data
- E-Learning Course: Health and Safety for Solid Dose Operators (Certified)
- New Data Presented at European Society of Cardiology Congress 2005 Reinforces Relative Safety of Low-Dose Aspirin Over Higher Doses
 |
 |
User Comments (0)
RSS Feeds